Therapeutics News and Research

RSS

Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

Mouth and throat cancers are the fastest rising cancers today. They account for over 40,000 cases per year in the U.S. The American Cancer Society estimates that there will be 121,790 new cases of head and neck cancer diagnosed in 2015 and 14,240 deaths. These numbers include tongue cancer, throat cancers caused by the human papillomavirus or HPV, voice box cancer, melanoma of the face and thyroid cancers.

8 Apr 2015

Experimental oligonucleotide-based drug stimulates human immune system to fight infections

An experimental single-stranded oligonucleotide-based drug, MGN1703, comprised only of natural DNA components, stimulates the human immune system to fight infections and attack cancer cells without causing the harmful side effects associated with similar compounds that also contain non-natural DNA components.

8 Apr 2015

RNA could be a potential target for new anticancer drugs, say UC Berkeley scientists

Most of today's anticancer drugs target the DNA or proteins in tumor cells, but a new discovery by University of California, Berkeley, scientists unveils a whole new set of potential targets: the RNA intermediaries between DNA and proteins.

7 Apr 2015

Nabriva Therapeutics completes $120 million Series B financing

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, today announced the successful completion of a $120 million Series B financing.

7 Apr 2015

Arvinas, Merck team up to create new therapeutics using protein degradation technology

Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.

7 Apr 2015

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

6 Apr 2015

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Sanford-Burnham Medical Research Institute today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.

6 Apr 2015

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Columbia Laboratories, Inc., today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol — "JNP" — on Monday, April 13, 2015.

2 Apr 2015

Omeros announces commercial availability of Omidria in U.S.

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, announced today the nationwide commercial availability of Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

2 Apr 2015

Penn Med's BLINKER Team named one of 16 finalists in NIH 'Follow that Cell Challenge'

James Eberwine, PhD, the Elmer Holmes Bobst Professor of Systems Pharmacology and Experimental Therapeutics, at the Perelman School of Medicine at the University of Pennsylvania, was named one of 16 finalists in the first phase of the Follow that Cell Challenge funded by the National Institutes of Health. The competition was run by crowdsourcing company Innocentive and 687 designated "solvers" entered initially.

2 Apr 2015

Novel molecule inhibits cancer-causing transcription factors

A novel molecule designed by scientists at the University of Massachusetts Medical School and the University of Virginia inhibits progression of a hard-to-treat form of recurring acute myeloid leukemia (AML) in patient tissue.

2 Apr 2015

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company’s investigational fully personalized immunotherapy for HIV.

2 Apr 2015

MD Anderson, NanoString Technologies collaborate to accelerate development of 'multi-omic' assays

The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a new type of assay based on NanoString's nCounter Analysis System.

From NanoString Technologies 1 Apr 2015

UTSA biologist recognized for showing leadership in advancing the discipline of reproductive biology

John McCarrey, professor of biology in the UTSA College of Sciences, has been selected to receive the Distinguished Service Award from the Society for the Study of Reproduction.

1 Apr 2015

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.

31 Mar 2015

Biomedical researchers successfully convert microbubble technology into nanoparticles

Biomedical researchers led by Dr. Gang Zheng at Princess Margaret Cancer Centre have successfully converted microbubble technology already used in diagnostic imaging into nanoparticles that stay trapped in tumours to potentially deliver targeted, therapeutic payloads.

31 Mar 2015

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Canadian and American health-care professionals will work together to study the effectiveness of advanced integrative oncology (AIO) treatment for patients with late stage cancer. AIO treatment includes elements of conventional and naturopathic medicine.

31 Mar 2015

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences today announced the presentation of a study that found drugs targeting specific pathways may have potentially significant benefit in a select subset of patients with uterine cancer. The study results were highlighted today in an oral presentation in a Plenary Session at the Society of Gynecologic Oncology 2015 Annual Meeting on Women's Cancer in Chicago, Ill.

30 Mar 2015

Columbia licenses exclusive worldwide rights to novel intra-vaginal ring technology

Columbia Laboratories, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, has licensed exclusive worldwide rights to a novel intra-vaginal ring technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring.

30 Mar 2015

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that the China Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.

30 Mar 2015

Therapeutics News and Research

Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

Experimental oligonucleotide-based drug stimulates human immune system to fight infections

RNA could be a potential target for new anticancer drugs, say UC Berkeley scientists

Nabriva Therapeutics completes $120 million Series B financing

Arvinas, Merck team up to create new therapeutics using protein degradation technology

MabVax closes $11.6 million in private placement

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Omeros announces commercial availability of Omidria in U.S.

Penn Med's BLINKER Team named one of 16 finalists in NIH 'Follow that Cell Challenge'

Novel molecule inhibits cancer-causing transcription factors

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

MD Anderson, NanoString Technologies collaborate to accelerate development of 'multi-omic' assays

UTSA biologist recognized for showing leadership in advancing the discipline of reproductive biology

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Biomedical researchers successfully convert microbubble technology into nanoparticles

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Columbia licenses exclusive worldwide rights to novel intra-vaginal ring technology

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

Next-generation therapeutics eBook eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News